Enliven Therapeutics CMO Helen Louise Collins disposes of USD 217,816 in common shares

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

ELVN

0.00
  • Enliven Therapeutics Chief Medical Officer Helen Louise Collins exercised options for 5,000 shares at USD 2.48 on June 17, 2026.
  • Collins sold 5,000 shares the same day at weighted average prices of about USD 42.83 to USD 44.74.
  • Directly held common shares fell to 25,000 following the transactions.
  • Stock options held rose to 121,268, with an exercise price of USD 2.48.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enliven Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001701247-26-000010), on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.